Kymera Therapeutics (KYMR) vs Repligen (RGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kymera Therapeutics (KYMR) has outperformed Repligen (RGEN) over the past year, gaining 94.2% versus a gain of 8.6%. Over five years, KYMR leads with a +91.1% price change compared with -38.6% for RGEN. Repligen is the larger company by market cap ($11.03 billion vs $9.28 billion), about 1.2 times the size.
Repligen converts more of its revenue into profit, with a net margin of 6.6% versus -794.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KYMR | RGEN |
|---|---|---|
| Share price | $112.80 | $173.79 |
| Market cap | $9.28B | $11.03B |
| 1-day change | +3.20% | +6.07% |
| YTD return | +40.47% | -0.01% |
| 1-year return | +94.17% | +8.64% |
| 5-year return | +91.08% | -38.62% |
| P/E ratio (TTM) | — | 238.07 |
| Forward P/E | — | 65.64 |
| EPS (TTM) | $-3.25 | $0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $39.21M | $738.26M |
| Revenue growth (YoY) | -16.70% | +16.36% |
| Net income (latest FY) | $-311.35M | $48.89M |
| Gross margin | 0.00% | 52.32% |
| Operating margin | -891.07% | 7.47% |
| Net margin | -794.04% | 6.62% |
| 52-week high | $130.05 | $198.87 |
| 52-week low | $55.26 | $100.99 |
| Distance from 52-week high | -13.26% | -12.61% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +23.51% | +12.18% |
| Average volume | 705.63K | 1.18M |
| Shares outstanding | 82.26M | 63.49M |
| Employees | 273 | 2,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KYMR has outperformed RGEN by 85.5 percentage points over the past year.
- Repligen is more profitable, keeping 6.6 cents of every revenue dollar as net income versus -794.0 cents for Kymera Therapeutics.
- Repligen grew revenue faster in its latest fiscal year (+16.36% vs -16.70%).
About Kymera Therapeutics
KYMR stock →Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 273 employees
About Repligen
RGEN stock →Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,000 employees
KYMR vs RGEN FAQ
Which is bigger, Kymera Therapeutics or Repligen?
Repligen (RGEN) is larger, with a market capitalization of $11.03B compared with $9.28B for Kymera Therapeutics (KYMR).
Which stock has performed better over the past year, KYMR or RGEN?
KYMR returned +94.17% over the past 12 months, compared with +8.64% for RGEN (price return, excluding dividends). Past performance does not predict future results.
Are Kymera Therapeutics and Repligen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.